NASDAQ:EOLSEvolus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evolus Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.58 -0.31 (-7.97 %) (As of 04/7/2020 03:49 PM ET) Add Compare Share Today's Range$3.51Now: $3.58▼$4.0350-Day Range$3.53MA: $6.31▼$10.4752-Week Range$3.12Now: $3.58▼$29.40Volume20,320 shsAverage Volume661,873 shsMarket Capitalization$120.75 millionP/E RatioN/ADividend YieldN/ABeta4.13 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus, Inc. is a subsidiary of ALPHAEON Corporation.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.75, Evolus has a potential upside of 507.5% from its current price of $3.58.Amount of Analyst CoverageEvolus has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesEvolus has received 284 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEvolus has received 227 “underperform” votes. (Add your “underperform” vote.)Community SentimentEvolus has received 55.58% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote “Outperform” if you believe EOLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $422,424.00 in company stock.Percentage Held by InsidersOnly 10.10% of the stock of Evolus is held by insiders.Percentage Held by Institutions41.50% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to decrease by -58.51% in the coming year, from ($2.41) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvolus has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EOLS Previous Symbol CUSIPN/A CIK1570562 Webhttp://www.evolus.com/ Phone949-284-4555Debt Debt-to-Equity Ratio0.97 Current Ratio6.23 Quick Ratio5.97Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.92 million Price / Sales3.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.38 per share Price / Book1.50Profitability EPS (Most Recent Fiscal Year)($3.19) Net Income$-90,030,000.00 Net MarginsN/A Return on Equity-196.32% Return on Assets-49.39%Miscellaneous Employees70 Outstanding Shares33,730,000Market Cap$120.75 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive EOLS News and Ratings via Email Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EOLS Rates by TradingView Evolus (NASDAQ:EOLS) Frequently Asked Questions How has Evolus' stock been impacted by COVID-19 (Coronavirus)? Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EOLS shares have decreased by 39.4% and is now trading at $3.58. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Evolus? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evolus. When is Evolus' next earnings date? Evolus is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Evolus. How were Evolus' earnings last quarter? Evolus Inc (NASDAQ:EOLS) posted its quarterly earnings results on Tuesday, February, 25th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.85) by $0.38. The company had revenue of $19.45 million for the quarter, compared to analyst estimates of $18.93 million. View Evolus' earnings history. What guidance has Evolus issued on next quarter's earnings? Evolus issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $34-35 million, compared to the consensus revenue estimate of $31.8 million. What price target have analysts set for EOLS? 8 brokers have issued 1-year price objectives for Evolus' stock. Their forecasts range from $9.00 to $35.00. On average, they anticipate Evolus' share price to reach $21.75 in the next twelve months. This suggests a possible upside of 507.5% from the stock's current price. View analysts' price targets for Evolus. What are Wall Street analysts saying about Evolus stock? Here are some recent quotes from research analysts about Evolus stock: 1. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (10/15/2019) 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution and ahead of what we expect to be a better-than-expected launch of Jeuveau, we are reiterating our OW rating and 12-month price target of $35. We think Jeuveau’s value proposition is underappreciated and that it will pick up more market share than anticipated. Therefore, the U.S. and other launches should drive EOLS’s stock higher, in our view." (4/30/2019) Has Evolus been receiving favorable news coverage? News coverage about EOLS stock has been trending very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evolus earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutEvolus. Are investors shorting Evolus? Evolus saw a decline in short interest in March. As of March 13th, there was short interest totaling 7,088,100 shares, a decline of 17.1% from the February 27th total of 8,550,000 shares. Based on an average trading volume of 941,400 shares, the days-to-cover ratio is currently 7.5 days. Currently, 31.7% of the company's stock are short sold. View Evolus' Current Options Chain. Who are some of Evolus' key competitors? Some companies that are related to Evolus include Clovis Oncology (CLVS), Nabriva Therapeutics (NBRV), Frequency Therapeutics (FREQ), Assembly Biosciences (ASMB), AC Immune (ACIU), Basilea Pharmaceutica (BPMUF), Prothena (PRTA), Athersys (ATHX), ANI Pharmaceuticals (ANIP), Emisphere Technologies (EMIS), Sinovac Biotech (SVA), DiaMedica Therapeutics (DMCAF), RAPT Therapeutics (RAPT), G1 Therapeutics (GTHX) and Xenon Pharmaceuticals (XENE). What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Canopy Growth (CGC), Calithera Biosciences (CALA), Tandem Diabetes Care (TNDM) and JD.Com (JD). Who are Evolus' key executives? Evolus' management team includes the following people: Mr. David Moatazedi, Pres, CEO & Director (Age 41)Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)Mr. Alejandro Sabad, VP of OperationsMr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury When did Evolus IPO? (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. What is Evolus' stock symbol? Evolus trades on the NASDAQ under the ticker symbol "EOLS." How do I buy shares of Evolus? Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Evolus' stock price today? One share of EOLS stock can currently be purchased for approximately $3.58. How big of a company is Evolus? Evolus has a market capitalization of $120.75 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe. View additional information about Evolus. What is Evolus' official website? The official website for Evolus is http://www.evolus.com/. How can I contact Evolus? Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Initial Coin Offering (ICO)
